Discontinuation of Heart Failure Medications in Patients Who Show Cardiac Function Improvement Following Atrial Fibrillation Treatment
Overview
This pilot randomized clinical trial investigates the feasibility and safety of phased withdrawal of guideline-directed medical therapy (GDMT) in patients with heart failure and improved ejection fraction following atrial fibrillation treatment.
Background
Atrial fibrillation (AF) and heart failure (HF) often coexist, leading to worsened outcomes due to their interrelated pathophysiology. Restoration of sinus rhythm through catheter ablation can improve cardiac function in patients with AF-mediated cardiomyopathy. However, the safety of discontinuing HF medications in patients who show improvement in cardiac function remains inadequately evaluated.
Data Highlights
No numerical data available in the provided source material.
Key Findings
The trial included patients aged 18 to 80 years with improved left ventricular ejection fraction (LVEF) post-ablation.
Eligible patients had LVEF of 55% or more and NT-proBNP levels less than 250 ng/L.
Patients were randomized to either phased GDMT withdrawal or continuation.
Medication withdrawal was conducted stepwise every 2 weeks, with specific adjustments based on medication type.
Patients were followed for 6 months to assess safety and feasibility.
Clinical Implications
Ongoing assessment of patients' cardiac status is essential during any medication adjustment.
Conclusion
This pilot trial seeks to clarify the safety of GDMT withdrawal in patients with heart failure who experience improved cardiac function following atrial fibrillation treatment.
